CompaniesCGI Pharmaceuticals

CGI Pharmaceuticals

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (8)
View all

Total Trials

8

As Lead Sponsor

3

As Collaborator

5

Total Enrollment

1,057

By Phase

PHASE1/PHASE2: 2PHASE2: 5

By Status

RECRUITING: 3COMPLETED: 3UNKNOWN: 1AVAILABLE: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
Today
NCT02139397
NCT02395666
NCT02559778
NCT04301843
NCT05249101
Hover over trial bars to see details

Recent Trials

NCT05249101Lead Sponsor
A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic Adenocarcinoma
PHASE1/PHASE2Recruiting
70 participants
Started: Aug 15, 2022 · Completed: Jun 30, 2026
NCT04301843Collaborator
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
PHASE2Recruiting
131 participants
Started: Sep 25, 2020 · Completed: Oct 1, 2033
NCT04438096Lead Sponsor
Safety and Efficacy of CVI-LM001 in Patients With Hypercholesterolemia
PHASE2Unknown
200 participants
Started: Jul 15, 2020 · Completed: Mar 15, 2022
NCT02559778Collaborator
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
PHASE2Recruiting
500 participants
Started: Sep 30, 2015 · Completed: Sep 30, 2035
NCT02395666Collaborator
Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission
PHASE2Completed
140 participants
Started: Mar 5, 2015 · Completed: Aug 24, 2023
View all 8 trials →